ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,051.09
0.00%
US Tech 100
21,191.20
0.62%
다우존스 지수
43,828.06
-0.20%
Bitcoin
101,722.92
0.26%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Innate Pharma SA (IPHA)

  7. Innate Pharma SA (IPHA) 뉴스

IPHA

Innate Pharma (IPHA)

Innate Pharma SA
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:IPHA
일자시간출처헤드라인심볼기업
2024/12/0920:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
2024/12/0915:00Business WireInnate Pharma présente à l’ASH 2024 des données de l’étude de Phase 2 TELLOMAK sur l’amélioration de la qualité de vie chez des patients atteints de lymphomes T cutanésNASDAQ:IPHAInnate Pharma SA
2024/12/0915:00Business WireInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell LymphomaNASDAQ:IPHAInnate Pharma SA
2024/12/0620:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
2024/12/0615:00Business WireInnate Pharma et l’Institut d’Innovation pour le Lymphome Folliculaire (IFLI) annoncent un investissement jusqu’à 7,9 millions de dollars de l’IFLI pour soutenir le développement d’IPH6501 dans le lymphome folliculaireNASDAQ:IPHAInnate Pharma SA
2024/12/0615:00Business WireInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular LymphomaNASDAQ:IPHAInnate Pharma SA
2024/12/0320:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
2024/12/0315:00Business WireInnate Pharma partage les présentations sélectionnées pour le congrès annuel de l’ASH 2024NASDAQ:IPHAInnate Pharma SA
2024/12/0315:00Business WireInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024NASDAQ:IPHAInnate Pharma SA
2024/11/2020:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
2024/11/2015:00Business WireInnate Pharma Releases Its 2025 Financial CalendarNASDAQ:IPHAInnate Pharma SA
2024/11/2015:00Business WireInnate Pharma publie son calendrier financier pour 2025NASDAQ:IPHAInnate Pharma SA
2024/11/1920:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
2024/11/1915:00Business WireInnate Pharma annonce une publication dans la revue Science Immunology mettant en avant le NK cell engager ANKET® de nouvelle génération IPH6501NASDAQ:IPHAInnate Pharma SA
2024/11/1915:00Business WireInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501NASDAQ:IPHAInnate Pharma SA
2024/11/1320:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
2024/11/1315:00Business WireInnate Pharma présente ses résultats financiers au troisième trimestre 2024NASDAQ:IPHAInnate Pharma SA
2024/11/1315:00Business WireInnate Pharma Reports Third Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
2024/11/0820:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
2024/11/0815:00Business WireInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024NASDAQ:IPHAInnate Pharma SA
2024/11/0815:00Business WireInnate Pharma annonce les présentations de données de son portefeuille innovant en oncologie sélectionnées pour le congrès annuel du SITC 2024NASDAQ:IPHAInnate Pharma SA
2024/11/0715:00Business WireInnate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business UpdatesNASDAQ:IPHAInnate Pharma SA
2024/11/0715:00Business WireInnate Pharma organise une conférence téléphonique pour ses résultats financiers et l’avancée de son portefeuille au troisième trimestre 2024NASDAQ:IPHAInnate Pharma SA
2024/10/2915:00Business WireInnate Pharma annonce sa participation à de prochaines conférences investisseursNASDAQ:IPHAInnate Pharma SA
2024/10/2915:00Business WireInnate Pharma Announces Its Participation in Upcoming Investor ConferencesNASDAQ:IPHAInnate Pharma SA
2024/10/1414:00Business WireInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive BoardNASDAQ:IPHAInnate Pharma SA
2024/10/1414:00Business WireJonathan Dickinson est nommé Président du Directoire d’Innate PharmaNASDAQ:IPHAInnate Pharma SA
2024/09/3014:00Business WireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024NASDAQ:IPHAInnate Pharma SA
2024/09/3014:00Business WireInnate Pharma co-organise un symposium scientifique en présence d’experts de l’Immunotherapie à New York le 3 octobre 2024NASDAQ:IPHAInnate Pharma SA
2024/09/2319:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
 검색 관련기사 보기:NASDAQ:IPHA

최근 히스토리

USOTC
BASFY
BASF (QX)
COIN
XRPUSD
Ripple
CCOM
US30
US 30
CCOM
SILVER
SILVER
CCOM
US500
US 500
COIN
DOGEUSD
Dogecoin
AMEX
XLF
Financial Select Sector
COIN
ADAUSD
Cardano
NASDAQ
NVDA
NVIDIA
FX
USDGBP
US Dollar vs Sterling
AMEX
XLV
Health Care Select Sector
FX
USDEUR
US Dollar vs Euro
NYSE
VZ
Verizon Communications
NASDAQ
TSLA
Tesla
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유